Wall Street has issued downbeat forecasts for the stocks in this article. These predictions are rare - financial institutions typically hesitate to say bad things about a company because it can jeopardize their other revenue-generating business lines like M&A advisory.
At StockStory, we look beyond the headlines with our independent analysis to determine whether these bearish calls are justified. Keeping that in mind, here is one stock where you should be greedy instead of fearful and two where the outlook is warranted.
Two Stocks to Sell:
RH (RH)
Consensus Price Target: $162.88 (-0.7% implied return)
Formerly known as Restoration Hardware, RH (NYSE: RH) is a specialty retailer that exclusively sells its own brand of high-end furniture and home decor.
Why Do We Think Twice About RH?
- Flat sales over the last three years suggest it must innovate and find new ways to grow
- Earnings per share have contracted by 39.2% annually over the last three years, a headwind for returns as stock prices often echo long-term EPS performance
- High net-debt-to-EBITDA ratio of 7× increases the risk of forced asset sales or dilutive financing if operational performance weakens
RH is trading at $164.04 per share, or 25.9x forward P/E. If you’re considering RH for your portfolio, see our FREE research report to learn more.
Myriad Genetics (MYGN)
Consensus Price Target: $6.25 (12.1% implied return)
Founded in 1991 as one of the pioneers in translating genetic discoveries into clinical applications, Myriad Genetics (NASDAQ: MYGN) develops genetic tests that assess disease risk, guide treatment decisions, and provide insights across oncology, women's health, and mental health.
Why Should You Dump MYGN?
- Annual revenue growth of 3.5% over the last two years was below our standards for the healthcare sector
- Negative returns on capital show that some of its growth strategies have backfired, and its shrinking returns suggest its past profit sources are losing steam
- Waning returns on capital from an already weak starting point displays the inefficacy of management’s past and current investment decisions
Myriad Genetics’s stock price of $5.58 implies a valuation ratio of 51.1x forward P/E. Check out our free in-depth research report to learn more about why MYGN doesn’t pass our bar.
One Stock to Watch:
Coca-Cola (KO)
Consensus Price Target: $85.97 (5.6% implied return)
A pioneer and behemoth in carbonated soft drinks, Coca-Cola (NYSE: KO) is a storied beverage company best known for its flagship soda.
Why Is KO Interesting?
- Unique products and pricing power lead to a best-in-class gross margin of 61.4%
- Highly efficient business model is illustrated by its impressive 27% operating margin, and its operating leverage amplified its profits over the last year
- Free cash flow margin increased by 27.5 percentage points over the last year, giving the company more capital to invest or return to shareholders
At $81.42 per share, Coca-Cola trades at 25x forward P/E. Is now a good time to buy? See for yourself in our comprehensive research report, it’s free.
High-Quality Stocks for All Market Conditions
ONE MORE THING: Top 6 Stocks for This Week. This market is separating quality stocks from expensive ones fast. AI is taking down whole sectors with no warning. In a rotation this fast, you need more than a list of good companies.
Our AI system flagged Palantir before it ran 1,662%. AppLovin before it ran 753%. Nvidia before it ran 1,178%. Each week it produces 6 new names that pass the same tests. Get Our Top 6 Stocks for Free HERE.
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today.
